Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

Vaccitech, a clinical-stage biopharmaceutical company, has announced the dosing of the first patient in its PCA001 clinical trial. The study is designed to determine the efficacy and safety of VTP-850 monotherapy in men with rising PSA after definitive local therapy for prostate cancer. VTP-850 is a next-generation immunotherapeutic candidate that uses two proprietary non-replicating viral vecto..